[ Inthera Bioscience raises $10.79M in Series A Funding ]

Inthera Bioscience has raised $10.79 million in Series A Funding.

Founded in 2013, Inthera Bioscience is a a Swiss biopharmaceutical company developing first-in-class targeted small molecule therapies for solid tumors.

The company  employs a proprietary technology platform to rationally design small molecule inhibitors of intracellular protein-protein interactions (PPIs). The company’s drug discovery programs are focused on the development of novel first-in-class oral agents blocking aberrant cell signaling in solid tumors, which are currently in pre-clinical development.

Funding  Series A
Founded  2013
Country  Swisse
City  Schlieren, Zurich
Founder / CEO  Ulrich Kessler
Deal Size  $10.79M
Investors  Novo Seeds
 Merck Ventures
 Aglaia BioMedical Ventures
Previous Investors  EVA Basel
 Microsoft Accelerator